logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer To Report Phase III EINSTEIN-PE Results In Late-BreakingTrials At ACC 2012

Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the Phase III EINSTEIN-PE study, with nearly 5,000 patients, would be presented in the Late-Breaking Clinical Trials Session on Monday, March 26th, 2012, 08:00 - 09:30am CDT, at the American College of Cardiology's 61st Annual Scientific Sessions or ACC in Chicago, USA, by lead investigator Harry Buller, MD, Academic Medical Center, Amsterdam, the Netherlands.

The EINSTEIN-PE study compared an oral single-drug approach with rivaroxaban, intensified initial treatment with rivaroxaban 15 mg twice daily for three weeks followed by 20 mg once daily, with the current standard of care of initial subcutaneous enoxaparin followed by a VKA in patients with acute symptomatic pulmonary embolism or PE with or without symptomatic deep vein thrombosis or DVT.

This multinational, randomized, event-driven trial with blinded outcome assessment was sponsored by Bayer HealthCare and Janssen Research & Development, LLC.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Retailer Sears Holdings Corp. reported Thursday wider net loss in its third quarter, hurt by weak revenues and comparable store sales. Edward Lampert, Chairman and Chief Executive Officer, said, "We remain fully committed to restoring profitability to our Company and are taking actions such as reducing unprofitable stores, reducing space in stores we continue to operate (including throug Sony announced Wednesday a temporary discount for the PlayStation 4, the same offer that was available on Black Friday and Cyber Monday. Starting December 11 and until December 24, the Japanese electronics maker will sell the Uncharted 4 PS4 Slim bundle for only $249.99 in the United States. A little over two months after reporting positive results from its first late-stage psoriasis trial, Dermira Inc. (DERM) is back with some more good news for its investors.
comments powered by Disqus
Follow RTT